VYNE Therapeutics (VYNE) Cash from Investing Activities Growth (1y) (2018 - 2026)
VYNE Therapeutics (VYNE) Cash from Investing Activities Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -76.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.30% |
| Jun 30, 2025 | -75.42% |
| Mar 31, 2025 | 655.65% |
| Dec 31, 2024 | 120.43% |
| Mar 31, 2024 | -171.38% |
| Dec 31, 2023 | -6,235,500.00% |
| Mar 31, 2023 | -68.26% |
| Jun 30, 2021 | -95.14% |
| Dec 31, 2020 | -66.82% |
| Jun 30, 2020 | -35.54% |
| Mar 31, 2020 | 752.56% |
| Dec 31, 2019 | -66.57% |
| Sep 30, 2019 | -156.38% |
| Jun 30, 2019 | 322.06% |
| Mar 31, 2019 | 116.87% |
| Dec 31, 2018 | 187.65% |
| Sep 30, 2018 | 122.85% |
| Jun 30, 2018 | 5.66% |
| Mar 31, 2018 | -704.53% |